These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 15367403)

  • 21. Pharmacogenomics of fluorouracil, irinotecan, and oxaliplatin in hepatic metastases of colorectal cancer: clinical implications.
    Lentz F; Tran A; Rey E; Pons G; Tréluyer JM
    Am J Pharmacogenomics; 2005; 5(1):21-33. PubMed ID: 15727486
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recent experience with oxaliplatin or irinotecan combined with 5-fluorouracil and leucovorin in the treatment of colorectal cancer.
    Kuebler JP; de Gramont A
    Semin Oncol; 2003 Aug; 30(4 Suppl 15):40-6. PubMed ID: 14523794
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Irinotecan or oxaliplatin combined with 5-fluorouracil and leucovorin as first-line therapy for advanced colorectal cancer: a meta-analysis.
    Liang XB; Hou SH; Li YP; Wang LC; Zhang X; Yang J
    Chin Med J (Engl); 2010 Nov; 123(22):3314-8. PubMed ID: 21163137
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The role of new agents in the treatment of colorectal cancer.
    Folprecht G; Köhne CH
    Oncology; 2004; 66(1):1-17. PubMed ID: 15031593
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Current and ongoing trials with irinotecan in the United States.
    Fuchs CS
    Semin Oncol; 2003 Aug; 30(4 Suppl 12):9-17. PubMed ID: 14508722
    [No Abstract]   [Full Text] [Related]  

  • 26. FOLFIRI as second-line chemotherapy after failure of FOLFOX4 in advanced colorectal cancer: a Korean single-center experience.
    Kim JH; Park SJ; Park MI; Moon W; Kim SE; Ku KH; Song SE; Kim JH
    Korean J Gastroenterol; 2014 Jan; 63(1):18-24. PubMed ID: 24463284
    [TBL] [Abstract][Full Text] [Related]  

  • 27. (Neo-)adjuvant treatments in colorectal cancer.
    Arnold D; Schmoll HJ
    Ann Oncol; 2005; 16 Suppl 2():ii133-40. PubMed ID: 15958444
    [No Abstract]   [Full Text] [Related]  

  • 28. Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
    Bajetta E; Celio L; Ferrario E; Di Bartolomeo M; Denaro A; Dotti K; Mancin M; Bajetta R; Colombo A; Pusceddu S
    Ann Oncol; 2007 Nov; 18(11):1810-6. PubMed ID: 17823385
    [TBL] [Abstract][Full Text] [Related]  

  • 29. What's new in ... colorectal cancer. Meaningful progress in therapy options.
    Polansky M; Ross AC
    JAAPA; 2009 Apr; 22(4):51-2. PubMed ID: 19452823
    [No Abstract]   [Full Text] [Related]  

  • 30. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multicenter phase II trial of dose-fractionated irinotecan in patients with advanced colorectal cancer failing oxaliplatin-based first-line combination chemotherapy.
    Ulrich-Pur H; Kornek GV; Fiebiger W; Gedlicka C; Raderer M; Lenauer A; Depisch D; Lang F; Pidlich J; Scheithauer W
    Ann Oncol; 2001 Sep; 12(9):1269-72. PubMed ID: 11697839
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of treatment with irinotecan and oxaliplatin combination in FU-resistant metastatic colorectal cancer patients.
    Bajetta E; Beretta E; Di Bartolomeo M; Cortinovis D; Ferrario E; Dognini G; Toffolatti L; Buzzoni R
    Oncology; 2004; 66(2):132-7. PubMed ID: 15138365
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparing time to disease progression of irinotecan and oxaliplatin-based chemotherapies in colorectal cancer patients with liver only metastasis.
    Varol U; Karaca B; Cakar B; Sezgin C; Karabulut B; Uslu R
    Am J Clin Oncol; 2013 Aug; 36(4):388-91. PubMed ID: 22643568
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Drug Insight: Metastatic colorectal cancer--oral fluoropyrimidines and new perspectives in the adjuvant setting.
    Folprecht G; Köhne CH
    Nat Clin Pract Oncol; 2005 Nov; 2(11):578-87. PubMed ID: 16270098
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oxaliplatin combined with irinotecan and 5-fluorouracil/leucovorin (OCFL) in metastatic colorectal cancer: a phase I-II study.
    Seium Y; Stupp R; Ruhstaller T; Gervaz P; Mentha G; Philippe M; Allal A; Trembleau C; Bauer J; Morant R; Roth AD
    Ann Oncol; 2005 May; 16(5):762-6. PubMed ID: 15817597
    [TBL] [Abstract][Full Text] [Related]  

  • 36. New chemotherapeutic strategies in colorectal cancer.
    Moehler M; Teufel A; Galle PR
    Recent Results Cancer Res; 2005; 165():250-9. PubMed ID: 15865041
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Irinotecan-related cholinergic syndrome induced by coadministration of oxaliplatin.
    Valencak J; Raderer M; Kornek GV; Henja MH; Scheithauer W
    J Natl Cancer Inst; 1998 Jan; 90(2):160. PubMed ID: 9450578
    [No Abstract]   [Full Text] [Related]  

  • 38. The use of irinotecan, oxaliplatin and raltitrexed for the treatment of advanced colorectal cancer: systematic review and economic evaluation.
    Hind D; Tappenden P; Tumur I; Eggington S; Sutcliffe P; Ryan A
    Health Technol Assess; 2008 May; 12(15):iii-ix, xi-162. PubMed ID: 18462574
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Current therapies for advanced colorectal cancer.
    Aggarwal S; Chu E
    Oncology (Williston Park); 2005 Apr; 19(5):589-95. PubMed ID: 15945340
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [The modern treatment of colorectal cancer. Present and future].
    András C; Farczádi E; Szántó J
    Orv Hetil; 2006 Mar; 147(9):409-14. PubMed ID: 16619959
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.